AICDA and B-cell non-Hodgkin lymphoma: Dysregulated AID activity due to SNPs can disrupt AID’s role in SHM and CSR, leading to immunodeficiency or defective antibody responses; as well, it may promote oncogenic mutations in MYC, BCL2 or PAX5, contributing to B-cell lymphomas.